Furthermore, a recent study indicated that metformin, a widely used anti‐diabetic drug, can mediate tumor suppression in an epigenetic pathway,74 and it has been reported that metformin can overcome CDK4/6 inhibitor resistance, and the addition of a methyltransferase inhibitor to CDK4/6i is likely to benefit patients with carcinomas.75 Here, CDK4 is linked to carcinoma.